Skip to main content
Evidence Snapshot

Rho-associated protein kinase 2

CHEMBL2973 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:19Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2973
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Rho-associated protein kinase 2 as ChEMBL target CHEMBL2973, mapped to UniProt O75116. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Rho-associated protein kinase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2973
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O75116
Rho-associated protein kinase 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Rho-associated protein kinase 2 matters

As of 2026-09-14

Rho-associated protein kinase 2 is reviewed as Rho-associated protein kinase 2 (UniProt O75116); Rho-associated protein kinase 2 shows approved-linked disease relevance led by immune system disease. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 24 approved drugs, 8425 compounds, and 744 assays, with lead potency reaching pChEMBL 10.8.

Disease context
immune system disease

Rho-associated protein kinase 2 shows approved-linked disease relevance led by immune system disease. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include BELUMOSUDIL.

Start review with immune system disease because it currently carries approved-linked support. Linked drugs include BELUMOSUDIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 1 linked drug
Activity base
Portfolio and assay base

ChEMBL currently tracks 24 approved drugs, 8425 compounds, and 744 assays for this target. The dominant activity type is IC50. CHEMBL3666733 is the current potency anchor at pChEMBL 10.8.

Use CHEMBL3666733 as the tractability anchor when discussing potency (pChEMBL 10.8).

Activity source · ChEMBL 36 via Core Engine
24 approved pChEMBL 10.8
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Rho-associated protein kinase 2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O75116, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why immune system disease is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

8425
Total Compounds
744
Total Assays
24
Approved Drugs
IC50: 7288.0, KI: 1245.0, EC50: 8.0, KD: 388.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL3666733
 10.8 IC50 —
No preferred name
CHEMBL2023843
 10.7 Kd —
No preferred name
CHEMBL525385
 10.7 Kd —
No preferred name
CHEMBL3666753
 10.6 IC50 —
No preferred name
CHEMBL3666735
 10.4 IC50 —

Approved Drugs

Structure Compound First Approval
MOMELOTINIB
CHEMBL1078178
 2023
CAPIVASERTIB
CHEMBL2325741
 2023
BELUMOSUDIL
CHEMBL2005186
 2021
UPADACITINIB
CHEMBL3622821
 2019
BARICITINIB
CHEMBL2105759
 2017
NETARSUDIL
CHEMBL4594250
 2017
PALBOCICLIB
CHEMBL189963
 2015
TOFACITINIB CITRATE
CHEMBL2103743
 2012
TOFACITINIB
CHEMBL221959
 2012
BOSUTINIB
CHEMBL288441
 2012
RUXOLITINIB
CHEMBL1789941
 2011
VANDETANIB
CHEMBL24828
 2011
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:19Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL2973